Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Deep Scientific Insights on Neostigmine Methylsulfate's R&D Progress
Drug Insights
4 min read
Deep Scientific Insights on Neostigmine Methylsulfate's R&D Progress
19 September 2023
This article summarized the latest R&D progress of Neostigmine Methylsulfate, the Mechanism of Action for Neostigmine Methylsulfate, and the drug target R&D trends for Neostigmine Methylsulfate.
Read →
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
Latest Hotspot
4 min read
Pierre Fabre Laboratories acquires Vertical Bio and its innovative targeted therapy for MET-altered Non-Small Cell Lung Cancer patients
19 September 2023
Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.
Read →
An In-depth Analysis of Milrinone Lactate's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Milrinone Lactate's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Milrinone Lactate, the Mechanism of Action for Milrinone Lactate, and the drug target R&D trends for Milrinone Lactate.
Read →
LSD1 inhibitors - A potent inhibitory target for tumor immunotherapy
LSD1 inhibitors - A potent inhibitory target for tumor immunotherapy
19 September 2023
LSD1, also known as lysine-specific demethylase 1A, is an enzyme that plays a crucial role in the regulation of gene expression in the human body.
Read →
Midazolam Hydrochloride: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Midazolam Hydrochloride: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Midazolam Hydrochloride, the Mechanism of Action for Midazolam Hydrochloride, and the drug target R&D trends for Midazolam Hydrochloride.
Read →
Exelixis and Insilico Medicine Enter into an exclusive global licensing deal for ISM3091
Latest Hotspot
3 min read
Exelixis and Insilico Medicine Enter into an exclusive global licensing deal for ISM3091
19 September 2023
Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.
Read →
Deep Scientific Insights on Metreleptin's R&D Progress, Mechanism of Action
Drug Insights
4 min read
Deep Scientific Insights on Metreleptin's R&D Progress, Mechanism of Action
19 September 2023
This article summarized the latest R&D progress of Metreleptin, the Mechanism of Action for Metreleptin, and the drug target R&D trends for Metreleptin.
Read →
Allergy Terminator: Leukotriene Receptor Antagonist
Allergy Terminator: Leukotriene Receptor Antagonist
19 September 2023
Leukotriene antagonists work by blocking the action of leukotrienes, they are mainly used for preventing asthma, controlling allergic rhinitis or allergic reactions.
Read →
An In-depth Analysis of Lonafarnib's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Lonafarnib's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Lonafarnib, the Mechanism of Action for Lonafarnib, and the drug target R&D trends for Lonafarnib.
Read →
BioLineRx reveals FDA approval for APHEXDA™ (motixafortide) to stimulate stem cell collection for autologous transplant in Multiple Myeloma patients
Latest Hotspot
4 min read
BioLineRx reveals FDA approval for APHEXDA™ (motixafortide) to stimulate stem cell collection for autologous transplant in Multiple Myeloma patients
19 September 2023
BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.
Read →
Ixabepilone: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Ixabepilone: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Ixabepilone, the Mechanism of Action for Ixabepilone, and the drug target R&D trends for Ixabepilone.
Read →
Another Potential Stock after PD1 - LAG3 Inhibitors
Another Potential Stock after PD1 - LAG3 Inhibitors
19 September 2023
The Lymphocyte-activation gene-3 (LAG-3) is located on human chromosome 12 (20p13.3), includes 8 exons, and its corresponding cDNA encodes a membrane protein containing 498 amino acids.
Read →